373 related articles for article (PubMed ID: 24414400)
1. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.
Parodi MB; Iacono P; La Spina C; Knutsson KA; Mansour A; Arevalo JF; Bandello F
Br J Ophthalmol; 2014 Apr; 98(4):519-22. PubMed ID: 24414400
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks.
Battaglia Parodi M; Iacono P; La Spina C; Berchicci L; Scotti F; Leys A; Introini U; Bandello F
Am J Ophthalmol; 2014 Feb; 157(2):374-377.e2. PubMed ID: 24211865
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study.
Iacono P; Battaglia Parodi M; La Spina C; Bandello F
Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis.
Parodi MB; Iacono P; Mansour A; Benedetto Ud; Knutsson KA; Bandello F; Ziemssen F; Ness T; Dodwell D
Retina; 2013 May; 33(5):953-6. PubMed ID: 23503338
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
